An update on antibody-based immunotherapies for Clostridium difficile infection

Clinical and Experimental Gastroenterology

Volumn 9, Issue , 2016, Pages 209-224

  Hussack, Greg ^a   Tanha, Jamshid ^a,b,c  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antibody; Clostridium difficile; Immunotherapy; Toxin

Indexed keywords

ACTOXUMAB; BEZLOTOXUMAB; BOTULINUM TOXIN A; BOTULINUM TOXIN B; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CA1125; MONOCLONAL ANTIBODY CA1151; MONOCLONAL ANTIBODY CA997; MONOCLONAL ANTIBODY PA 50; UNCLASSIFIED DRUG;

BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; NONHUMAN; REVIEW; TREATMENT OUTCOME;

EID: 84983356570     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S84017     Document Type: Review

References (162)

1. Ghose C. Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect. 2013;2(9):e62.
2. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015; 372(16):1539–1548.
3. Rea MC, Dobson A, O’Sullivan O, et al. Effect of broad- and narrowspectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A. 2011; 108(suppl 1):4639–4644.
4. Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection –focus on fidaxomicin. Infect Drug Resist. 2013;6:41–53.
5. Mullane K. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther Adv Chronic Dis. 2014;5(2):69–84.
6. Hussack G, Tanha J. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins. 2010;2(5):998–1018.
7. Simon MR, Chervin SM, Brown SC. Polyclonal antibody therapies for Clostridium difficile infection. Antibodies. 2014;3(4):272–288.
8. Humphreys DP, Wilcox MH. Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol. 2014;21(7):913–923.
9. Mathur H, Rea MC, Cotter PD, Ross RP, Hill C. The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes. 2014;5(6):696–710.
10. Ivarsson ME, Leroux JC, Castagner B. Investigational new treatments for Clostridium difficile infection. Drug Discov Today. 2015;20(5): 602–608.
11. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7(7):526–536.
12. Mizrahi A, Collignon A, Péchiné S. Passive and active immunization strategies against Clostridium difficile infections: state of the art. Anaerobe. 2014;30:210–219.
13. Jank T, Aktories K. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol. 2008;16(5):222–229.
14. Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology. 2007;17(4):15R–22R.
15. Lyras D, O’Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458(7242):1176–1179.
16. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467(7316):711–713.
17. Govind R, Dupuy B. Secretion of Clostridium difficile toxins A and B requires the holin-like protein TcdE. PLoS Pathog. 2012;8(6):e1002727.
18. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010;28(4):965–969.
19. Katchar K, Taylor CP, Tummala S, Chen X, Sheikh J, Kelly CP. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol. 2007;5(6):707–713.
20. Monaghan TM, Robins A, Knox A, Sewell HF, Mahida YR. Circulating antibody and memory B-cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis. PLoS One. 2013;8(9):e74452.
21. Aktories K. Bacterial protein toxins that modify host regulatory GTPases. Nat Rev Microbiol. 2011;9(7):487–498.
22. El Feghaly RE, Bangar H, Haslam DB. The molecular basis of Clostridium difficile disease and host response. Curr Opin Gastroenterol. 2015;31(1):24–29.
23. Solomon K. The host immune response to Clostridium difficile infection. Ther Adv Infect Dis. 2013;1(1):19–35.
24. Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015;14(11):737–738.
25. Oleksiewicz MB, Nagy G, Nagy E. Anti-bacterial monoclonal antibodies: back to the future? Arch Biochem Biophys. 2012;526(2): 124–131.
26. Bebbington C, Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol. 2008;19(6):613–619.
27. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun. 1998;66(5):2018–2025.
28. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun. 1991;59(6):2215–2218.
29. Roberts A, McGlashan J, Al-Abdulla I, et al. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun. 2012;80(2):875–882.
30. van Dissel JT, de Groot N, Hensgens CM, et al. Bovine antibodyenriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol. 2005;54(pt 2):197–205.
31. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci. 2011;56(1):19–26.
32. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5): 548–558.
33. Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine. 2008;26(27–28):3404–3409.
34. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine. 2009;27(suppl 6):G38–G46.
35. Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov. 2006;5(3): 191–195.
36. Kim DY, Hussack G, Kandalaft H, Tanha J. Mutational approaches to improve the biophysical properties of human single-domain antibodies. Biochim Biophys Acta. 2014;1844(11):1983–2001.
37. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–797.
38. Zielonka S, Empting M, Grzeschik J, Könning D, Barelle CJ, Kolmar H. Structural insights and biomedical potential of IgNAR scaffolds from sharks. MAbs. 2015;7(1):15–25.
39. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126–1136.
40. Kim DS, Song HN, Nam HJ, et al. Directed evolution of human heavy chain variable domain (VH) using in vivo protein fitness filter. PLoS One. 2014;9(6):e98178.
41. Hussack G, Hirama T, Ding W, Mackenzie R, Tanha J. Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS One. 2011;6(11):e28218.
42. Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol. 2004;22(9):1161–1165.
43. To R, Hirama T, Arbabi-Ghahroudi M, et al. Isolation of monomeric human VHs by a phage selection. J Biol Chem. 2005;280(50): 41395–41403.
44. Christ D, Famm K, Winter G. Repertoires of aggregation-resistant human antibody domains. Protein Eng Des Sel. 2007;20(8):413–416.
45. Dudgeon K, Rouet R, Kokmeijer I, et al. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A. 2012;109(27):10879–10884.
46. Rouet R, Lowe D, Christ D. Stability engineering of the human antibody repertoire. FEBS Lett. 2014;588(2):269–277.
47. Famm K, Hansen L, Christ D, Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol. 2008;376(4):926–931.
48. Hussack G, Riazi A, Ryan S, et al. Protease-resistant single-domain antibodies inhibit Campylobacter jejuni motility. Protein Eng Des Sel. 2014;27(6):191–198.
49. Kim DY, Kandalaft H, Ding W, et al. Disulfide linkage engineering for improving biophysical properties of human VH domains. Protein Eng Des Sel. 2012;25(10):581–589.
50. Harmsen MM, van Solt CB, van Zijderveld-van Bemmel AM, Niewold TA, van Zijderveld FG. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol. 2006;72(3):544–551.
51. Desmyter A, Spinelli S, Roussel A, Cambillau C. Camelid nanobodies: killing two birds with one stone. Curr Opin Struct Biol. 2015;32:1–8.
52. Griffiths K, Dolezal O, Parisi K, et al. Shark variable new antigen receptor (VNAR) single domain antibody fragments: stability and diagnostic applications. Antibodies. 2013;2(1):66–81.
53. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009;284(5):3273–3284.
54. Ben Abderrazek R, Vincke C, Hmila I, et al. Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII scorpion toxin. Protein Eng Des Sel. 2011;24(9):727–735.
55. Kovalenko OV, Olland A, Piché-Nicholas N, et al. Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis. J Biol Chem. 2013;288(24):17408–17419.
56. Kovaleva M, Ferguson L, Steven J, Porter A, Barelle C. Shark variable new antigen receptor biologics –a novel technology platform for therapeutic drug development. Expert Opin Biol Ther. 2014;14(10): 1527–1539.
57. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficileinduced mortality in hamsters. Infect Immun. 2006;74(11):6339–6347.
58. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3): 197–205.
59. Davies NL, Compson JE, Mackenzie B, et al. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol. 2013;20(3):377–390.
60. Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83(2):822–831.
61. Orth P, Xiao L, Hernandez LD, et al. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. 2014;289(26): 18008–18021.
62. Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis. 2013;207(2):323–330.
63. Anosova NG, Cole LE, Li L, et al. A combination of three fully human toxin A- and toxin B-specific monoclonal antibodies protects against challenge with highly virulent epidemic strains of Clostridium difficile in the Hamster Model. Clin Vaccine Immunol. 2015;22(7):711–725.
64. Marozsan AJ, Ma D, Nagashima KA, et al. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis. 2012;206(5):706–713.
65. Lyerly DM, Phelps CJ, Toth J, Wilkins TD. Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun. 1986;54(1):70–76.
66. Frey SM, Wilkins TD. Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun. 1992;60(6):2488–2492.
67. Demarest SJ, Hariharan M, Elia M, et al. Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs. 2010;2(2): 190–198.
68. Modi N, Gulati N, Solomon K, et al. Differential binding and internalization of Clostridium difficile toxin A by human peripheral blood monocytes, neutrophils and lymphocytes. Scand J Immunol. 2011;74(3): 264–271.
69. Lyerly DM, Phelps CJ, Wilkins TD. Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol. 1985;21(1):12–14.
70. Zhang C, Jin K, Xiao Y, et al. Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization. Hum Vaccin Immunother. 2013;9(10):2157–2164.
71. He X, Sun X, Wang J, et al. Antibody-enhanced, Fc gamma receptormediated endocytosis of Clostridium difficile toxin A. Infect Immun. 2009;77(6):2294–2303.
72. He X, Wang J, Steele J, et al. An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods. 2009;78(1):97–100.
73. Steele J, Chen K, Sun X, et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis. 2012;205(3):384–391.
74. Corthier G, Muller MC, Wilkins TD, Lyerly D, L’Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun. 1991;59(3):1192–1195.
75. Hussack G, Arbabi-Ghahroudi M, Mackenzie CR, Tanha J. Isolation and characterization of Clostridium difficile toxin-specific singledomain antibodies. Methods Mol Biol. 2012;911:211–239.
76. Hussack G, Arbabi-Ghahroudi M, van Faassen H, et al. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem. 2011;286(11): 8961–8976.
77. Hussack G, Keklikian A, Alsughayyir J, et al. A VL single-domain antibody library shows a high-propensity to yield non-aggregating binders. Protein Eng Des Sel. 2012;25(6):313–318.
78. Murase T, Eugenio L, Schorr M, et al. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile. J Biol Chem. 2013;289(4):2331–2343.
79. Shkoporov AN, Khokhlova EV, Savochkin KA, Kafarskaia LI, Efimov BA. Production of biologically active scFv and VHH antibody fragments in Bifidobacterium longum. FEMS Microbiol Lett. 2015;362(12):fnv083.
80. Yang Z, Schmidt D, Liu W, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis. 2014;210(6):964–972.
81. Andersen KK, Strokappe NM, Hultberg A, et al. Neutralization of Clostridium difficile toxin B mediated by engineered lactobacilli producing single domain antibodies. Infect Immun. 2015;84(2):395–406.
82. Péchiné S, Janoir C, Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J Clin Microbiol. 2005;43(10):5018–5025.
83. Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother. 2014;10(6):1466–1477.
84. Ghose C, Kelly CP. The prospect for vaccines to prevent Clostridium difficile infection. Infect Dis Clin North Am. 2015;29(1):145–162.
85. Wang S, Rustandi RR, Lancaster C, et al. Toxicity assessment of Clostridium difficile toxins in rodent models and protection of vaccination. Vaccine. 2016;34(10):1319–1323.
86. Gerding DN, Johnson S, Rupnik M, Aktories K. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes. 2014;5(1):15–27.
87. Janoir C. Virulence factors of Clostridium difficile and their role during infection. Anaerobe. 2016;37:13–24.
88. Unger M, Eichhoff AM, Schumacher L, et al. Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT. Sci Rep. 2015;5:7850.
89. Fagan RP, Fairweather NF. Biogenesis and functions of bacterial S-layers. Nat Rev Microbiol. 2014;12(3):211–222.
90. Sleytr UB, Beveridge TJ. Bacterial S-layers. Trends Microbiol. 1999;7(6):253–260.
91. Calabi E, Ward S, Wren B, et al. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol. 2001;40(5):1187–1199.
92. Calabi E, Calabi F, Phillips AD, Fairweather NF. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun. 2002;70(10):5770–5778.
93. Drudy D, O’Donoghue DP, Baird A, Fenelon L, O’Farrelly C. Flow cytometric analysis of Clostridium difficile adherence to human intestinal epithelial cells. J Med Microbiol. 2001;50(6):526–534.
94. Merrigan MM, Venugopal A, Roxas JL, et al. Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. PLoS One. 2013;8(11):e78404.
95. Takumi K, Susami Y, Takeoka A, Oka T, Koga T. S layer protein of Clostridium tetani: purification and properties. Microbiol Immunol. 1991;35(7):569–575.
96. Stevenson E, Minton NP, Kuehne SA. The role of flagella in Clostridium difficile pathogenicity. Trends Microbiol. 2015;23(5): 275–282.
97. Tasteyre A, Barc MC, Collignon A, Boureau H, Karjalainen T. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun. 2001;69(12):7937–7940.
98. Mulvey GL, Dingle TC, Fang L, Strecker J, Armstrong GD. Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection. J Med Microbiol. 2011;60(pt 8):1181–1187.
99. Pantaléon V, Soavelomandroso AP, Bouttier S, et al. The Clostridium difficile protease Cwp84 modulates both biofilm formation and cellsurface properties. PLoS One. 2015;10(4):e0124971.
100. O’Brien JB, McCabe MS, Athié-Morales V, McDonald GS, Ní Eidhin DB, Kelleher DP. Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins. FEMS Microbiol Lett. 2005;246(2):199–205.
101. Péchiné S, Janoir C, Boureau H, et al. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine. 2007;25(20):3946–3954.
102. Ní Eidhin DB, O’Brien JB, McCabe MS, Athié-Morales V, Kelleher DP. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol. 2008;52(2):207–218.
103. Drudy D, Calabi E, Kyne L, et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol. 2004;41(3):237–242.
104. Kandalaft H, Hussack G, Aubry A, et al. Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease. Appl Microbiol Biotechnol. 2015;99(20):8549–8562.
105. Péchiné S, Denéve C, Le Monnier A, Hoys S, Janoir C, Collignon A. Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol Med Microbiol. 2011;63(1):73–81.
106. Sandolo C, Péchiné S, Le Monnier A, et al. Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile. Eur J Pharm Biopharm. 2011;79(3):566–573.
107. Ganeshapillai J, Vinogradov E, Rousseau J, Weese JS, Monteiro MA. Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydr Res. 2008;343(4):703–710.
108. Oberli MA, Hecht ML, Bindschädler P, Adibekian A, Adam T, Seeberger PH. A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol. 2011;18(5):580–588.
109. Monteiro MA, Ma Z, Bertolo L, et al. Carbohydrate-based Clostridium difficile vaccines. Expert Rev Vaccines. 2013;12(4):421–431.
110. Adamo R, Romano MR, Berti F, et al. Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to Clostridium difficile PSII cell wall polysaccharide. ACS Chem Biol. 2012;7(8):1420–1428.
111. Romano MR, Leuzzi R, Cappelletti E, et al. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity. Toxins. 2014;6(4):1385–1396.
112. Dapa T, Unnikrishnan M. Biofilm formation by Clostridium difficile. Gut Microbes. 2013;4(5):397–402.
113. Reid CW, Vinogradov E, Li J, Jarrell HC, Logan SM, Brisson JR. Structural characterization of surface glycans from Clostridium difficile. Carbohydr Res. 2012;354:65–73.
114. Cox AD, St Michael F, Aubry A, et al. Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection. Glycoconj J. 2013;30(9):843–855.
115. Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs. 2012;4(2):182–197.
116. Castoldi R, Jucknischke U, Pradel LP, et al. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigenbinding properties. Protein Eng Des Sel. 2012;25(10):551–559.
117. Jachimowicz RD, Borchmann S, Rothe A. Multi-specific antibodies for cancer immunotherapy. BioDrugs. 2014;28(4):331–343.
118. Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics. 2013;10(1):1–18.
119. Dimasi N, Fleming R, Hay C, et al. Development of a trispecific antibody designed to simultaneously and efficiently target three different antigens on tumor cells. Mol Pharm. 2015;12(9):3490–3501.
120. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2 pt A):95–106.
121. DiGiandomenico A, Keller AE, Gao C, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6(262):262ra155.
122. Kingwell K. Infectious diseases: two-hit antibody tackles bacteria. Nat Rev Drug Discov. 2015;14(1):15.
123. Zhang Z, Chen X, Hernandez LD, et al. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun. 2015;83(1):405–416.
124. Jones RG, Martino A. Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. Crit Rev Biotechnol. 2016;36(3):506–520.
125. Reilly RM, Domingo R, Sandhu J. Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet. 1997;32(4):313–323.
126. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol. 2008;6(5):349–362.
127. Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut. 2007;56(6):888–889.
128. Tjellström B, Stenhammar L, Eriksson S, Magnusson KE. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet. 1993;341(8846):701–702.
129. Rahman S, Van Nguyen S, Icatlo FC Jr, Umeda K, Kodama Y. Oral passive IgY-based immunotherapeutics: a novel solution for prevention and treatment of alimentary tract diseases. Hum Vaccin Immunother. 2013;9(5):1039–1048.
130. Kim DY, To R, Kandalaft H, et al. Antibody light chain variable domains and their biophysically improved versions for human immunotherapy. MAbs. 2014;6(1):219–235.
131. Pant N, Hultberg A, Zhao Y, et al. Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis. 2006; 194(11):1580–1588.
132. Krüger C, Hu Y, Pan Q, et al. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol. 2002;20(7):702–706.
133. Martín MC, Pant N, Ladero V, et al. Integrative expression system for delivery of antibody fragments by lactobacilli. Appl Environ Microbiol. 2011;77(6):2174–2179.
134. Andersen KK, Marcotte H, Álvarez B, Boyaka PN, Hammarström L. In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli. BMC Biotechnol. 2011;11:126.
135. de Marco A. Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs. Microb Cell Fact. 2015;14:125.
136. Álvarez B, Krogh-Andersen K, Tellgren-Roth C, et al. An exopolysaccharide-deficient mutant of Lactobacillus rhamnosus GG efficiently displays a protective llama antibody fragment against rotavirus on its surface. Appl Environ Microbiol. 2015;81(17):5784–5793.
137. Günaydin G, Álvarez B, Lin Y, Hammarström L, Marcotte H. Coexpression of anti-rotavirus proteins (llama VHH antibody fragments) in Lactobacillus: development and functionality of vectors containing two expression cassettes in tandem. PLoS One. 2014;9(4): e96409.
138. Pant N, Marcotte H, Hermans P, et al. Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. Future Microbiol. 2011;6(5):583–593.
139. Beninati C, Oggioni MR, Boccanera M, et al. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat Biotechnol. 2000;18(10):1060–1064.
140. Maffey L, Vega CG, Parreno V, Garaicoechea L. Controlling Rotavirusassociated diarrhea: could single-domain antibody fragments make the difference? Rev Argent Microbiol. 2015;47(4):368–379.
141. Cheung AT, Dayanandan B, Lewis JT, et al. Glucose-dependent insulin release from genetically engineered K cells. Science. 2000; 290(5498):1959–1962.
142. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6):868–876.
143. Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor a VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006;54(6):1856–1866.
144. Terryn S, Francart A, Lamoral S, et al. Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice. PLoS One. 2014;9(10):e109367.
145. Gainkam LO, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008;49(5):788–795.
146. Vugmeyster Y, Entrican CA, Joyce AP, et al. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol). Bioconjug Chem. 2012;23(7):1452–1462.
147. Rashidian M, Wang L, Eden JG, et al. Enzyme-mediated modification of single-domain antibodies for imaging modalities with different characteristics. Angew Chem Int Ed Engl. 2016;55(2): 528–533.
148. Iqbal U, Trojahn U, Albaghdadi H, et al. Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br J Pharmacol. 2010;160(4): 1016–1028.
149. Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther. 2008;7(8):2288–2297.
150. Müller MR, Saunders K, Grace C, et al. Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. MAbs. 2012;4(6):673–685.
151. Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs. 2015;29(4):215–239.
152. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013;1830(12):5526–5534.
153. Rotman M, Welling MM, van den Boogaard ML, et al. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake. Nucl Med Biol. 2015;42(8):695–702.
154. Richard G, Meyers AJ, McLean MD, Arbabi-Ghahroudi M, MacKenzie R, Hall JC. In vivo neutralization of a-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody. PLoS One. 2013;8(7):e69495.
155. Pruitt RN, Chambers MG, Ng KK, Ohi MD, Lacy DB. Structural organization of the functional domains of Clostridium difficile toxins A and B. Proc Natl Acad Sci U S A. 2010;107(30):13467–13472.
156. Chumbler NM, Rutherford SA, Zhang Z, et al. Crystal structure of Clostridium difficile toxin A. Nat Microbiol. 2016;1(1):15002.
157. Albesa-Jove D, Bertrand T, Carpenter EP, et al. Four distinct structural domains in Clostridium difficile toxin B visualized using SAXS. J Mol Biol. 2010;396(5):1260–1270.
158. Pruitt RN, Chumbler NM, Rutherford SA, et al. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity. J Biol Chem. 2012;287(11):8013–8020.
159. Bradshaw WJ, Kirby JM, Thiyagarajan N, et al. The structure of the cysteine protease and lectin-like domains of Cwp84, a surface layerassociated protein from Clostridium difficile. Acta Crystallogr D Biol Crystallogr. 2014;70(pt 7):1983–1993.
160. Bradshaw WJ, Roberts AK, Shone CC, Acharya KR. Cwp84, a Clostridium difficile cysteine protease, exhibits conformational flexibility in the absence of its propeptide. Acta Crystallogr F Struct Biol Commun. 2015;71(pt 3):295–303.
161. Gutelius D, Hokeness K, Logan SM, Reid CW. Functional analysis of SleC from Clostridium difficile: an essential lytic transglycosylase involved in spore germination. Microbiology. 2014;160(pt 1): 209–216.
162. Twine SM, Reid CW, Aubry A, et al. Motility and flagellar glycosylation in Clostridium difficile. J Bacteriol. 2009;191(22):7050–7062.